

# Pfizer COVID-19 Vaccination Schedule

		Months			
Age & Indication	COVID-19 Vax History	0	1	2	3
Pfizer <sup>a, d</sup> for 6 months - 4 years	Unvaccinated	1st bivalent dose	2nd bivalent dose <sup>b</sup> (3-8 weeks after 1st)		3rd bivalent dose (>8 weeks after 2nd)
	1 dose of monovalent		1st bivalent dose <sup>b</sup> (3-8 weeks after monovalent dose)		2nd bivalent dose (>8 weeks after 1st)
	2 or 3 doses of monovalent			1 bivalent dose (>8 weeks after last monovalent dose)	
	2 doses of monovalent + 1 dose of bivalent				
Pfizer <sup>a, c, d</sup> for ≥5 years	Unvaccinated	1 bivalent dose			
	1+ dose of monovalent (no doses of bivalent mRNA)			1 bivalent dose (>8 weeks after last monovalent dose)	
	Ever received bivalent booster regardless of monovalent vaccine history				

a. Monovalent boosters are no longer authorized for this age group.

b. An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

c. For adults 65 years and older, a single, additional, age-appropriate bivalent dose may be administered at least 4 months following the initial dose of bivalent COVID-19 vaccine.

d. **For people who are moderately or severely immunocompromised:** At the time of initial vaccination, people ages ≥6 months are recommended to receive 3 bivalent mRNA doses. People ages ≥6 months who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses depending on age and vaccine product. People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1+ additional bivalent mRNA doses. Any additional doses must be determined by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

# Moderna COVID-19 Vaccination Schedule

		Months			
Age & Indication	COVID-19 Vax History	0	1	2	3
Moderna <sup>a, d</sup> for 6 months - 5 years	Unvaccinated	1st bivalent dose	2nd bivalent dose <sup>b</sup> (4-8 weeks after 1st)		
	1 dose of monovalent		1 bivalent dose <sup>b</sup> (4-8 weeks after monovalent dose)		
	2 doses of monovalent			1 bivalent dose (>8 weeks after last monovalent dose)	
	2 doses of monovalent + 1 dose of bivalent				
Moderna <sup>a, c, d</sup> for ≥6 years	Unvaccinated	1 bivalent dose			
	1+ dose of monovalent (no doses of bivalent mRNA)			1 bivalent dose (>8 weeks after last monovalent dose)	
	Ever received bivalent booster regardless of monovalent vaccine history				


a. Monovalent boosters are no longer authorized for this age group.

b. An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

c. For adults 65 years and older, a single, additional, age-appropriate bivalent dose may be administered at least 4 months following the initial dose of bivalent COVID-19 vaccine.

d. **For people who are moderately or severely immunocompromised:** At the time of initial vaccination, people ages ≥6 months are recommended to receive 3 bivalent mRNA doses. People ages ≥6 months who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses depending on age and vaccine product. People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1+ additional bivalent mRNA doses. Any additional doses must be determined by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

# Novavax COVID-19 Vaccination Schedule



a. The primary series doses are separated by 3–8 weeks. An 8-week interval between the first and second primary series doses might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with this vaccine.

b. Monovalent boosters are no longer authorized for this age group. People ages 12 years and older who previously received 1 or more doses of Novavax COVID-19 Vaccine are recommended to receive 1 bivalent mRNA vaccine dose (e.g. Pfizer or Moderna).

## Additional Information on COVID-19 Boosters

### c. People ages 65 years and older

For adults 65 years and older, a single, additional, age-appropriate bivalent dose may be administered at least 4 months following the initial dose of bivalent COVID-19 vaccine.

### d. People who are moderately or severely immunocompromised

People ages 12 years and older who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine or Pfizer COVID-19 Vaccine at least 2 months following the last recommended bivalent COVID-19 vaccine dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

### e. For LIMITED situations

Novavax can be used as a booster dose in limited situations for people ages 18 years and older who previously completed primary vaccination using any FDA-approved or FDA-authorized COVID-19 vaccine; have not received any previous booster dose(s); and are unable (i.e., mRNA vaccine contraindicated or not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. The monovalent Novavax booster dose is administered at least 6 months after completion of any primary series.

## Want more information on COVID-19 vaccine schedules?

- CDC Interim Clinical Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html>
- NDDoH COVID-19 Vaccine Information: <https://www.hhs.nd.gov/health/coronavirus/vaccine-information>

# COVID-19 Vaccination Schedules for People Who are Moderately or Severely Immunocompromised

## Pfizer COVID-19 Vaccination Schedule for People Who are Moderately or Severely Immunocompromised

		Months			
Age & Indication	COVID-19 Vax History	0	1	2	3
Pfizer <sup>a</sup> for 6 months - 4 years	Unvaccinated	1st bivalent dose	2nd bivalent dose (3 weeks after 1st)		3rd bivalent dose (>8 weeks after 2nd)
	1 dose of monovalent		1st bivalent dose (3 weeks after last monovalent dose)		2nd bivalent dose (>8 weeks after 1st)
	2 or 3 doses of monovalent			1 bivalent dose (>8 weeks after last monovalent dose)	
	2 or 3 doses of monovalent + 1 dose of bivalent			*OPTIONAL* Additional bivalent dose	
Pfizer <sup>a</sup> for ≥5 years	Unvaccinated	1st bivalent dose	2nd bivalent dose (3 weeks after 1st)	3rd bivalent dose (>4 weeks after 2nd)	
	1 dose of monovalent		1st bivalent dose (3 weeks after last monovalent dose)	2nd bivalent dose (>4 weeks after 1st)	
	2 doses of monovalent		1st bivalent dose (>4 weeks after last monovalent dose)		
	3 doses of monovalent			1st bivalent dose (>8 weeks after last monovalent dose)	
	3 doses of monovalent + 1 dose of bivalent			*OPTIONAL* Additional bivalent dose	

a. For people who are moderately or severely immunocompromised: At the time of initial vaccination, people ages >6 months are recommended to receive 3 bivalent mRNA doses. People ages >6 months who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses depending on age and vaccine product. People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1+ additional bivalent mRNA doses. Any additional doses must be determined by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

## Moderna COVID-19 Vaccination Schedule for People Who are Moderately or Severely Immunocompromised

		Months			
Age & Indication	COVID-19 Vax History	0	1	2	3
Moderna <sup>a</sup> for 6 months and older	Unvaccinated	1st bivalent dose	2nd bivalent dose (4 weeks after 1st dose)		3rd bivalent dose (>4 weeks after 2nd dose)
	1 dose of monovalent		1st bivalent dose (4 weeks after last monovalent dose)		2nd bivalent dose (>4 weeks after 1st dose)
	2 doses of monovalent		1 bivalent dose (>4 weeks after last monovalent dose)		
	3 doses of monovalent			1 bivalent dose (>8 weeks after last monovalent dose)	
	3 doses of monovalent + 1 dose of bivalent			*OPTIONAL* Additional bivalent dose	

a. For people who are moderately or severely immunocompromised: At the time of initial vaccination, people ages >6 months are recommended to receive 3 bivalent mRNA doses. People ages >6 months who previously received only monovalent doses are recommended to receive 1 or 2 bivalent mRNA vaccine doses depending on age and vaccine product. People who previously received a bivalent mRNA vaccine dose(s) have the option to receive 1+ additional bivalent mRNA doses. Any additional doses must be determined by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.

## Novavax COVID-19 Vaccination Schedule for People Who are Moderately or Severely Immunocompromised

		Months			
Age & Indication	COVID-19 Vax History	0	1	2	3
Novavax <sup>a</sup> ≥12 years	1 or 2 doses of Novavax vaccine			1 mRNA (Moderna OR Pfizer) bivalent dose (>8 weeks after last monovalent dose)	

a. People ages 12 years and older who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine or Pfizer COVID-19 Vaccine at least 2 months following the last recommended bivalent COVID-19 vaccine dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose.


### Novavax COVID-19 Vaccine remains authorized to provide:

- A 2-dose primary series to people ages 12 years and older. The primary series doses are separated by 3–8 weeks. An 8-week interval between the first and second primary series doses might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with this vaccine.
- A booster dose in limited situations to people ages 18 years and older who previously completed primary vaccination using any FDA-approved or FDA-authorized COVID-19 vaccine; have not received any previous booster dose(s); and are unable (i.e., contraindicated or vaccine not available) or unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. The monovalent Novavax booster dose is administered at least 6 months after completion of any primary series.

## COVID-19 Risk Continuum

Lower Risk

Higher Risk



*The most important risk factor is increasing age.*

This figure outlines several considerations that impact risk for COVID-19, which exists on a continuum and is highly individualized. Listed comorbidities and immunosuppressive conditions are illustrative, not exhaustive; there is significant variability in the net state of immunocompromise even among people with the same condition.

Figure created by the Infectious Diseases Society of America. You may access the original graphic at <https://www.idsociety.org/covid-19-real-time-learning-network/special-populations/immunocompromised-populations/>.